How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi,Bernard Zinman,David Fitchett,Christoph Wanner,Ele Ferrannini,Martin Schumacher,Claudia Schmoor,Kristin Ohneberg,Odd Erik Johansen,Jyothis T. George,Stefan Hantel,Erich Bluhmki,John M. Lachin +12 more
TLDR
In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.Abstract:
OBJECTIVE In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 diabetes and established cardiovascular (CV) disease, empagliflozin given in addition to standard of care reduced the risk of CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses the extent to which treatment group differences in covariates during the trial contributed to CV death risk reduction with empagliflozin. RESEARCH DESIGN AND METHODS Effects of potential mediators, identified post hoc, on the HR for CV death with empagliflozin versus placebo were analyzed by Cox regression models, with treatment group adjusted for the baseline value of the variable and its change from baseline or updated mean (i.e., considering all prior values), each as a time-dependent covariate. HRs were compared with a model without adjustment for covariates. Multivariable analyses also were performed. RESULTS Changes in hematocrit and hemoglobin mediated 51.8% and 48.9%, respectively, of the effect of empagliflozin versus placebo on the risk of CV death on the basis of changes from baseline, with similar results in analyses on the basis of updated means. Smaller mediation effects (maximum 29.3%) were observed for uric acid, fasting plasma glucose, and HbA 1c . In multivariable models, which incorporated effects of empagliflozin on hematocrit, fasting glucose, uric acid, and urine albumin:creatinine ratio, the combined changes from baseline provided 85.2% mediation, whereas updated mean analyses provided 94.6% mediation of the effect of empagliflozin on CV death. CONCLUSIONS In this exploratory analysis from the EMPA-REG OUTCOME trial, changes in markers of plasma volume were the most important mediators of the reduction in risk of CV death with empagliflozin versus placebo.read more
Citations
More filters
Journal ArticleDOI
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Faiez Zannad,João Pedro Ferreira,Stuart J. Pocock,Stefan D. Anker,Javed Butler,Gerasimos Filippatos,Martina Brueckmann,Anne Pernille Ofstad,Egon Pfarr,Waheed Jamal,Milton Packer +10 more
TL;DR: The pooled treatment effects showed consistent benefits for subgroups based on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but suggested treatment-by-subgroup interactions for sub groups based on NYHA functional class and race.
Journal ArticleDOI
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma,John J.V. McMurray +1 more
TL;DR: The role of SGLT2 inhibitors in optimising ventricular loading conditions through their effect on diuresis and natriuresis, in addition to reducing afterload and improving vascular structure and function is focused on.
Journal ArticleDOI
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K. McGuire,Weichung Shih,Weichung Shih,Francesco Cosentino,Bernard Charbonnel,David Z.I. Cherney,Samuel Dagogo-Jack,Richard E. Pratley,Michelle Greenberg,Shuai Wang,Susan Huyck,Ira Gantz,Steven G. Terra,Urszula Masiukiewicz,Christopher P. Cannon +14 more
TL;DR: This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.
Journal ArticleDOI
Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Iain C. Macdougall,Andreas J. Bircher,Kai-Uwe Eckardt,Gregorio T. Obrador,Carol A. Pollock,Carol A. Pollock,Peter Stenvinkel,Dorine W. Swinkels,Christoph Wanner,Günter Weiss,Glenn M. Chertow,John W. Adamson,Tadao Akizawa,Stefan D. Anker,Michael Auerbach,Peter Bárány,Anatole Besarab,Sunil Bhandari,Ioav Cabantchik,Alan J. Collins,Daniel W. Coyne,Angel L.M. de Francisco,Steven Fishbane,Carlo A. J. M. Gaillard,Tomas Ganz,David Goldsmith,Chaim Hershko,Ewa A. Jankowska,Kirsten L. Johansen,Kamyar Kalantar-Zadeh,Philip A. Kalra,Bertram L. Kasiske,Francesco Locatelli,Jolanta Malyszko,Gert Mayer,Lawrence P. McMahon,Ashraf Mikhail,Elizabeta Nemeth,Amy Barton Pai,Patrick S. Parfrey,Roberto Pecoits-Filho,Simon D. Roger,Guy Rostoker,Jacques Rottembourg,Ajay K. Singh,Itzchak Slotki,Bruce Spinowitz,Der Cherng Tarng,Francesca Tentori,Jorge E. Toblli,Yusuke Tsukamoto,Nosratola D. Vaziri,Wolfgang C. Winkelmayer,David C. Wheeler,Elena Zakharova +54 more
TL;DR: An expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.
Journal ArticleDOI
The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen,Jesper Lau +1 more
TL;DR: Rational design has led to the development of two long-acting GLP-1 analogs, liraglutide and semaglUTide, that have made a vast contribution to the management of T2D in terms of improvements in glycemic control, body weight, blood pressure, lipids, beta-cell function, and CV outcomes.
References
More filters
Journal ArticleDOI
The moderator–mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations.
Reuben M. Baron,David A. Kenny +1 more
TL;DR: This article seeks to make theorists and researchers aware of the importance of not using the terms moderator and mediator interchangeably by carefully elaborating the many ways in which moderators and mediators differ, and delineates the conceptual and strategic implications of making use of such distinctions with regard to a wide range of phenomena.
Journal ArticleDOI
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
Diabetes Control,David M. Nathan,Saul M. Genuth,John M. Lachin,Patricia A. Cleary,O Crofford,Matthew M. Davis,Larry Rand,Carolyn Siebert +8 more
TL;DR: Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.
Journal ArticleDOI
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman,Christoph Wanner,John M. Lachin,David Fitchett,Erich Bluhmki,Stefan Hantel,Michaela Mattheus,Theresa Devins,Odd Erik Johansen,Hans-Juergen Woerle,Uli C. Broedl,Silvio E. Inzucchi +11 more
TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
TL;DR: Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up.
Book
Introduction to Statistical Mediation Analysis
TL;DR: In this paper, the authors introduce the statistical, methodological, and conceptual aspects of mediation analysis applications from health, social, and developmental psychology, sociology, communication, exercise science, and epidemiology are emphasized throughout Singlemediator, multilevel, and longitudinal models are reviewed.
Related Papers (5)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray,Scott D. Solomon,Silvio E. Inzucchi,Lars Køber,Mikhail Kosiborod,Felipe Martinez,Piotr Ponikowski,Marc S. Sabatine,Marc S. Sabatine,Inder S. Anand,Jan Bělohlávek,Michael Böhm,Chern-En Chiang,Chern-En Chiang,Vijay K. Chopra,Rudolf A. de Boer,Akshay S. Desai,Mirta Diez,Jarosław Drożdż,Andrej Dukát,Junbo Ge,Jonathan G. Howlett,Jonathan G. Howlett,Tzvetana Katova,Masafumi Kitakaze,Charlotta Ljungman,Béla Merkely,Jose C. Nicolau,Eileen O'Meara,Mark C. Petrie,Pham Nguyen Vinh,Morten Schou,Tereshchenko Sn,Subodh Verma,Claes Held,David L. DeMets,Kieran F. Docherty,Pardeep S. Jhund,Olof Bengtsson,Mikaela Sjöstrand,AM Langkilde +40 more
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more